drugset / Trial / NCT06314698
Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease
RandomizedParallel-groupOpen-labelSupportive care
Summary
The purpose of this study is to determine if narlumosbart is non-inferior to denosumab in the treatment of bone diseases from multiple myeloma (MM).
Timeline
- Start
- 2024-04-01
- Primary completion
- 2024-12-31
- Completion
- 2027-04-30
Publications
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Denosumab | Monoclonal antibody | 120 mg | Subcutaneous |
| Subject | Narlumosbart | Monoclonal antibody | 120 mg | Subcutaneous |